{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Subcutaneous+insulin", "query": { "intervention": "Subcutaneous insulin" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 352, "total_pages": 36, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Subcutaneous+insulin&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-04T03:24:15.310Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02794155", "title": "Study of HDV Insulin Versus Insulin in Type 1 Diabetes Subjects (ISLE-1)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 1 Diabetes Mellitus" ], "interventions": [ { "name": "HDV Insulin Lispro", "type": "DRUG" }, { "name": "Insulin LISPRO", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Diasome Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 157, "start_date": "2016-06", "completion_date": "2018-06-15", "has_results": false, "last_update_posted_date": "2018-07-31", "last_synced_at": "2026-09-04T03:24:15.310Z", "location_count": 21, "location_summary": "Corona, California • Los Angeles, California • Northridge, California + 18 more", "locations": [ { "city": "Corona", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Northridge", "state": "California" }, { "city": "San Carlos", "state": "California" }, { "city": "San Mateo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02794155" }, { "nct_id": "NCT01311076", "title": "TAK-329 Glucose Clamp Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Type 1 Diabetes Mellitus" ], "interventions": [ { "name": "TAK-329", "type": "DRUG" }, { "name": "Insulin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 37, "start_date": "2011-03", "completion_date": "2012-01", "has_results": false, "last_update_posted_date": "2012-02-13", "last_synced_at": "2026-09-04T03:24:15.310Z", "location_count": 1, "location_summary": "Chula Vista, California", "locations": [ { "city": "Chula Vista", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01311076" }, { "nct_id": "NCT03713684", "title": "Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Efpeglenatide SAR439977", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Background therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 370, "start_date": "2018-11-09", "completion_date": "2021-01-04", "has_results": true, "last_update_posted_date": "2021-12-02", "last_synced_at": "2026-09-04T03:24:15.310Z", "location_count": 22, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Huntington Park", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03713684" }, { "nct_id": "NCT01768559", "title": "Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Lixisenatide (AVE0010)", "type": "DRUG" }, { "name": "Insulin glulisine QD", "type": "DRUG" }, { "name": "Insulin glulisine TID", "type": "DRUG" }, { "name": "Insulin Glargine (Mandatory background drug)", "type": "DRUG" }, { "name": "Metformin (Background drug)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 894, "start_date": "2013-01", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2017-01-04", "last_synced_at": "2026-09-04T03:24:15.310Z", "location_count": 46, "location_summary": "Sun City, Arizona • Tempe, Arizona • Little Rock, Arkansas + 41 more", "locations": [ { "city": "Sun City", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Mesa", "state": "California" }, { "city": "Mission Viejo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01768559" }, { "nct_id": "NCT05184868", "title": "AT247, NovoLog® and Fiasp® Administered Via Continuous Subcutaneous Infusion in Glucose Clamp Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diabetes Mellitus, Type 1" ], "interventions": [ { "name": "AT247", "type": "DRUG" }, { "name": "NovoLog", "type": "DRUG" }, { "name": "Fiasp", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arecor Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 24, "start_date": "2022-01-03", "completion_date": "2022-09-09", "has_results": false, "last_update_posted_date": "2022-09-13", "last_synced_at": "2026-09-04T03:24:15.310Z", "location_count": 1, "location_summary": "Chula Vista, California", "locations": [ { "city": "Chula Vista", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05184868" }, { "nct_id": "NCT05790681", "title": "A Study to Test How New Long-acting Insulin (Insulin Icodec) Works in the Body of Children and Teenagers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Insulin icodec", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "10 Years to 18 Years" }, "enrollment_count": 18, "start_date": "2023-04-25", "completion_date": "2024-02-08", "has_results": false, "last_update_posted_date": "2026-04-09", "last_synced_at": "2026-09-04T03:24:15.310Z", "location_count": 21, "location_summary": "Los Angeles, California • New Haven, Connecticut • Jacksonville, Florida + 12 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05790681" }, { "nct_id": "NCT00229658", "title": "An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Type 1 Diabetes Mellitus", "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "pramlintide acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1297, "start_date": "2005-09", "completion_date": "2008-05", "has_results": true, "last_update_posted_date": "2015-03-25", "last_synced_at": "2026-09-04T03:24:15.310Z", "location_count": 107, "location_summary": "Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 104 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Encinitas", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00229658" }, { "nct_id": "NCT00322257", "title": "Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 1" ], "interventions": [ { "name": "inhaled human insulin", "type": "DRUG" }, { "name": "insulin detemir", "type": "DRUG" }, { "name": "insulin aspart", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 596, "start_date": "2006-05-01", "completion_date": "2008-04-02", "has_results": false, "last_update_posted_date": "2018-09-05", "last_synced_at": "2026-09-04T03:24:15.310Z", "location_count": 86, "location_summary": "Birmingham, Alabama • Tuscaloosa, Alabama • Concord, California + 78 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Concord", "state": "California" }, { "city": "Encino", "state": "California" }, { "city": "Escondido", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00322257" }, { "nct_id": "NCT03434119", "title": "Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Insulin glargine/Lixisenatide", "type": "DRUG" }, { "name": "Insulin glargine (HOE901)", "type": "DRUG" }, { "name": "Background therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 241, "start_date": "2018-02-20", "completion_date": "2019-01-07", "has_results": true, "last_update_posted_date": "2022-03-28", "last_synced_at": "2026-09-04T03:24:15.310Z", "location_count": 85, "location_summary": "Montgomery, Alabama • Little Rock, Arkansas • Anaheim, California + 63 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03434119" }, { "nct_id": "NCT04398030", "title": "Pharmacokinetics (PK)/ Pharmacodynamics (PD) of an Extended Wear Infusion Set for Continuous Subcutaneous Insulin Infusion (CSII) in Type 1 Diabetes Mellitus (T1DM) Patients (\"PEXIS\")", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Diabetes Mellitus, Type 1", "Type 1 Diabetes" ], "interventions": [ { "name": "coil-reinforced soft polymer indwelling cannula", "type": "DEVICE" }, { "name": "soft Teflon indwelling catheter", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Capillary Biomedical, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 7, "start_date": "2020-07-17", "completion_date": "2021-04-22", "has_results": true, "last_update_posted_date": "2022-08-11", "last_synced_at": "2026-09-04T03:24:15.310Z", "location_count": 1, "location_summary": "Escondido, California", "locations": [ { "city": "Escondido", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04398030" } ] }